Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth

• Started clinical trial with lead candidate RJx-01 for treating sarcopenia
• Expands the team and moved to new offices and lab

Diepenbeek, Health Campus, Belgium, 29 March 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, today provides an update on its development pipeline and strategy.

Read more...

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH